SOHO 2023: CLL

Patrick DalyConferences | September 15, 2023
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Read More
Patrick DalyConferences | September 15, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Patrick DalyConferences | September 15, 2023
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Patrick DalyConferences | September 15, 2023
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
Advertisement
Advertisement